Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index; 263 of the 340 sources its claims cite were checked for support.
Abstract
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide, with a significant impact on public health. Current treatment options include surgery, chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy. Despite advancements in these therapeutic modalities, resistance remains a significant challenge, often leading to treatment failure, poor progression-free survival, and cancer recurrence. Mechanisms of resistance in CRC are multifaceted, involving genetic mutations, epigenetic alterations, tumor heterogeneity, and the tumor microenvironment. Understanding these mechanisms at the molecular level is crucial for identifying novel therapeutic targets and developing strategies to overcome resistance. This review provides an overview of the diverse mechanisms driving drug resistance in sporadic CRC and discusses strategies currently under investigation to counteract this resistance. Several promising strategies are being explored, including targeting drug transport, key signaling pathways, DNA damage response, cell death pathways, epigenetic modifications, cancer stem cells, and the tumor microenvironment. The integration of emerging therapeutic approaches that target resistance mechanisms aims to enhance the efficacy of current CRC treatments and improve patient outcomes.
Overview
CoChat Summary
TL;DR
This review summarizes the diverse mechanisms driving drug resistance in sporadic colorectal cancer (CRC)—including drug transport/metabolism, signaling pathway alterations, DNA damage response and cell death defects, epigenetic changes, tumor heterogeneity/CSCs/DTPs, and the tumor microenvironment—and discusses therapeutic strategies under investigation to overcome it. It concludes that combination approaches targeting multiple resistance mechanisms, guided by molecular profiling, hold the most promise.
Key findings
- Drug resistance in CRC is multifactorial and can be intrinsic or acquired; recurrence occurs in 30–40% of patients who complete treatment, mostly within the first 2–3 years, and resistance has been reported to develop in nearly all CRC patients. Mechanisms include ABC transporter–mediated efflux (PGP/MDR1, BCRP, MRP1/2), altered drug metabolism (GSTs, UGTs, CYPs), secondary mutations/alternative pathway activation (EGFR, RAS/BRAF, PI3K/AKT/mTOR, HER2/MET), enhanced DNA damage response, defective apoptosis/autophagy, epigenetic alterations, CSCs, EMT, DTPs, and the TME.
- Key molecular features: APC mutated in ~80% of CRCs, KRAS ~40%, BRAF 10–15%, TP53 50–60%, SMAD4 ~15%, PIK3CA ~20%; CIN accounts for ~85% of sporadic CRCs, MSI ~15%, CIMP ~20%. Consensus molecular subtypes: 87% of samples assigned to CMS1–4 (CMS1 14%, CMS2 37%, CMS3 13%, CMS4 23%), with 13% mixed features.
- Strategies under investigation include targeting ABC transporters (e.g., miRNA mimics miR-133b, miR-142-3p, miR-297, miR-522; nanomedicine), EGFR and alternative pathways (Sym004, anti-HER2/anti-MET, KRAS-G12C inhibitors sotorasib/adagrasib, BRAF+EGFR+MEK combinations), DDR (PARP, ATM, WEE1 inhibitors), cell death pathways (BH3 mimetics, IAP antagonist TL32711, chloroquine/hydroxychloroquine, ferroptosis inducers RSL3/erastin), epigenetic therapies (DNMT, HDAC, EZH2, KDM1A/KDM4 inhibitors; ncRNA modulation), CSCs (LGR5 antibody–drug conjugates, MCLA-158, BiTEs, oncolytic viruses, Wnt/Notch/Hh inhibition, differentiation therapy), and the TME (anti-angiogenic agents, HIF inhibitors, hypoxia-activated prodrug evofosfamide, ECM/LOX targeting, CAF targeting, ICIs, CAR-T cells).
- The review concludes that CRC heterogeneity and multiple resistance mechanisms make it unlikely that one therapy can eliminate all CRC cells; combination therapies and precision medicine guided by genomic, epigenomic, and molecular profiling are emphasized.
Methods
- Design: narrative review providing an overview of drug resistance mechanisms in sporadic CRC and strategies under investigation to counteract resistance.
- Data: published literature, with references cited throughout; no primary patient data or experimental study is reported.
- Main analysis: narrative synthesis of mechanisms and therapeutic approaches; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.
Limitations
- Stated: the paper does not include an explicit limitations section for the review itself.
- Evident: as a narrative review, it lacks a described systematic search strategy, inclusion/exclusion criteria, and quantitative synthesis, so selection and interpretation of evidence may be subject to bias.
- Evident: the scope is sporadic CRC, and many discussed strategies are preclinical or still under investigation, with clinical utility and biomarker-based patient selection not yet established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
219 Valid · 5 Not valid · 40 Not checked · 59 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Polymeric polylactide-co-glycolic acid (PLGA) NPs were also shown to increase the cytotoxicity of chemotherapy drugs, such as 5-FU and irinotecan, in CRC cell lines [113,114].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 4. Strategies to Overcome Drug Resistance > 4.1. Targeting ABC Membrane Transporters
What the sources say
- Not checked — no full text of the sourcecites [113] Emami, 2018, PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan, Pharm. Dev. Technol. source
- Disputedcites [114] Ghasemi Toudeshkchouei, M., Zahedi, P., and Shavandi, A. (2020). Microfluidic-Assisted Preparation of 5-Fluorouracil-Loaded PLGA Nanoparticles as a Potential System for Colorectal Cancer Therapy. Materials, 13. sourceExperimental — accuracy not yet measured
In Results and Discussion §3.5 (page unavailable), the paper reports more cell death with neat 5-FU than with 5-FU-loaded PLGA nanoparticles in both CRC cell lines—the opposite of increased cytotoxicity relative to the free drug. The study evaluates 5-FU, not irinotecan. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“CRC is commonly associated with mutations in key driver genes including APC, KRAS, BRAF, TP53, SMAD4, and PIK3CA [12].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 1. Introduction > 1.3. Genetic Mutations and Associated Molecular Pathways
What the sources say
- Supportedcites [12] Carethers, 2015, Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer, Gastroenterology source
The sections on non-hypermutated sporadic CRCs describe APC, KRAS, PIK3CA, TP53 and SMAD4 as altered genes, including mutations and, for some, loss of heterozygosity. The section on hypermutated sporadic CRCs identifies BRAF mutation as common in sporadic MSI-H CRCs. No page numbers are provided in the supplied passages. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“CRC presents different types of epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA (ncRNA)-associated changes [21,23].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 1. Introduction > 1.4. Epigenetic Alterations and Associated Molecular Pathways
What the sources say
- Supportedcites [21] Jung, 2020, Epigenetics of colorectal cancer: Biomarker and therapeutic potential, Nat. Rev. Gastroenterol. Hepatol. source
The Principles of epigenetics section identifies DNA methylation, histone modifications, and ncRNA regulators as implicated in CRC. The Introduction likewise lists these as topics of epigenetic alteration and regulation in CRC. (LLM, conf=0.95)
- Supportedcites [23] Sadida, 2024, Epigenetic modifications: Key players in cancer heterogeneity and drug resistance, Transl. Oncol. source
The review’s “Epigenetic mechanisms in cancer” section identifies DNA methylation, histone modification, and non-coding RNA as epigenetic mechanisms. Its discussion of colorectal cancer also gives examples involving methylation and histone acetylation, and links miR-126 expression to colorectal cancer. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 3. Mechanisms of Drug Resistance > 3.1. Drug Transport and Metabolism
What the sources say
- Supportedcites [43] Puris, E., Fricker, G., and Gynther, M. (2023). The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy. Pharmaceutics, 15. source
Section 4 states that insufficient anticancer drug delivery into cancer cells can result from down-regulation of membrane influx transporters. Section 6 identifies acquired down-regulation of SLC transporters responsible for anticancer drug uptake as a cause of ineffective treatment. The paper frames this as a mechanism of anticancer drug resistance, without quantifying how common it is. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the tumor microenvironment (TME) plays a significant role in mediating resistance.”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 3. Mechanisms of Drug Resistance
What the sources say
- Supportedcites [41] Wang, Q., Shen, X., Chen, G., and Du, J. (2022). Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 14. source
Section 9, “Tumor Microenvironment,” states that TME components can act as therapeutic barriers and provide a sanctuary in which tumor cells escape drug-mediated death and develop resistance. The Conclusions also explicitly identify the TME as a focus in drug resistance. The provided passages do not give page numbers. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
165 more claims · 118 with their cited sources checked
Create a free account to see all 323 claims and to verify the 3 references still open.
- It may state two separate claims as one. 130
- Probably not a substantial claim. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of Class I PI3K, occur in approximately 15–20% of colorectal cancers and represent one of the most common alterations affecting this pathway [17,18].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF is a serine/threonine protein kinase (signal transduction protein) and activating mutations in it accounts for around ten to fifteen percent of CRCs, mainly the BRAF V600E—a point mutation and a biomarker of poor prognosis [18,20,21,22].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in RAS, importantly, the KRAS-mutated tumors, are associated with around forty percent of CRCs [12,18,19], while NRAS is less frequent but remains a clinically relevant contributor to tumor heterogeneity.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 2. Therapeutic Approaches for Colorectal Cancer > 2.2. Targeted Therapies
“Anti-EGFR therapies, such as EGFR tyrosine kinase inhibitors cetuximab and panitumumab, block or slow down the growth of tumor cells.”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 4. Strategies to Overcome Drug Resistance > 4.2. Targeting EGFR and Alternative Pathways
“Targeting molecules involved in these resistance mechanisms would help to overcome resistance to anti-EGFR monoclonal antibody (mAb) therapies like cetuximab and panitumumab.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Furthermore, EGF-targeted 5-FU-loaded PLGA NPs were developed to selectively target CRC cells expressing high levels of EGFR and showed higher rates of cytotoxicity and apoptosis and lower rates of tumor growth compared to non-targeted or non-NP treatments [115].”
Cited work 10.1186/s12885-020-06803-7 · retracted 2026-08-22 · notice 10.1186/s12885-026-16805-6 · this paper published 2025-02-25
Citations
Cites
1 retracted
Items 201–244 of 244
CD166-specific CAR-T cells potently target colorectal cancer cells
He, S., Li, S., Guo, J., Zeng, X., Liang, D., Zhu, Y., Li, Y., Yang, D., & Zhao, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2022.101575 · Cited by 30 · cited 1×
“For instance, CAR-T cells currently under development for targeting colorectal CSCs include CD133, EpCAM-, or CD166-directed CAR-T cells [229–232].”
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30 · cited 7×
“A second key approach for targeting colorectal CSCs involves the suppression of specific signaling pathways that are critical for CSC maintenance and proliferation [69,71,72].”
InfluentialKarthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., et al. (2022) · Life · doi:10.3390/life12060811 · Cited by 30 · cited 2×
“Furthermore, defective apoptotic pathways can contribute to MDR [45].”
Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
Kao, A. T., Cabanlong, C. V., Padilla, K., & Xue, X. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.025 · Cited by 30 · cited 2×
“The use of ferroptosis inducers in CRC cells can promote iron-dependent lipid peroxidation, leading to cell death [141].”
E, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-014-2667-5 · Cited by 29
The Synergistic Effect of 5-Aza-2′-Deoxycytidine and 5-Fluorouracil on Drug-Resistant Tumors
Morita, S., Iida, S., Kato, K., Takagi, Y., Uetake, H., & Sugihara, K. (2006) · Oncology · doi:10.1159/000107110 · Cited by 29 · cited 1×
“Moreover, DNMT inhibitors were demonstrated to restore 5-FU sensitivity to 5-FU-resistant CRC cells in mouse xenograft tumor models [162,163].”
Hsu, H.-C., Liu, Y.-S., Tseng, K.-C., Yang, T.-S., Yeh, C.-Y., You, J.-F., Hung, H.-Y., Chen, S.-J., & Chen, H.-C. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1782-4 · Cited by 29 · cited 1×
“On the other hand, inhibiting Lysine Demethylase 1A (KDM1A; demethylase for H3K4 and H3K9) suppressed CRC cell proliferation through downregulation of the Wnt/ β -catenin pathway [174].”
Therapeutic Targets of KRAS in Colorectal Cancer
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021) · Cancers · doi:10.3390/cancers13246233 · Cited by 28 · cited 1×
“Other approaches under investigation to target mutant KRAS in CRC include perturbing the interaction between KRAS and the plasma membrane, and the combined inhibition of downstream pathways [122].”
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28 · cited 1×
“Moreover, DNMT inhibitors were demonstrated to restore 5-FU sensitivity to 5-FU-resistant CRC cells in mouse xenograft tumor models [162,163].”
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., et al. (2023) · Cancers · doi:10.3390/cancers15051471 · Cited by 27 · cited 1×
“Nevertheless, inhibiting Hh signaling in CRC cells has been shown to be effective in reducing cell viability and expression of CSC markers and may also enhance chemosensitivity at least in some cellular contexts [200–202].”
Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26 · cited 1×
“Dysregulation of ncRNAs, such as miRNAs and lncRNAs, can lead to altered drug sensitivity and resistance in CRC cells [60].”
Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W., Quackenbush, K. S., Schreiber, A., Messersmith, W. A., Devaraj, K. M., Blatchford, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22920 · Cited by 26 · cited 1×
“For instance, a selective ATM inhibitor was shown to enhance the sensitivity of CRC cell lines to irinotecan in vitro and confer drug sensitivity to CRC patient-derived xenografts that were resistant to irinotecan monotherapy [139].”
Therapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26 · cited 3×
“Resisting cell death is an important hallmark of cancer cells and a key contributor to therapy resistance in CRC. Apoptosis is a non-lytic form of programmed cell death (type I) and is the primary mechanism by which therapies use to eliminate cancer cells [52].”
(2009) · PubMed · Cited by 26
Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development
Thein, K. Z., Myat, Y. M., Park, B. S., Panigrahi, K., & Kummar, S. (2024) · Cancers · doi:10.3390/cancers16142529 · Cited by 26
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24 · cited 4×
“Furthermore, T cells can be engineered to express CARs that selectively target CSC markers, leading to improved recognition and destruction of CSCs, which are commonly resistant to T cell therapy [180].”
InfluentialTherapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24 · cited 1×
“Additionally, PARP inhibitors have also shown efficacy when used in combination with DNA-damaging agents such as chemotherapy and radiotherapy [50,134].”
Zargar, P., Ghani, E., Mashayekhi, F., Ramezani, A., & Eftekhar, E. (2018) · Oncology Letters · doi:10.3892/ol.2018.8569 · Cited by 23
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1715 · Cited by 22 · cited 1×
“Furthermore, evofosfamide was shown to effectively reduce CRC tumor growth and CSC numbers when administered sequentially after 5-FU treatment [217].”
Self-citationIdrissi, M. B., Bouhaddouti, H. E., Mouaqit, O., Ousadden, A., Taleb, K. A., & Benjelloun, E. B. (2023) · Cureus · doi:10.7759/cureus.37563 · Cited by 22
Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0082-y · Cited by 22 · cited 1×
“Furthermore, the IAP antagonist TL32711 was demonstrated to sensitize CRC cell lines to 5-FU-or oxaliplatin-induced cell death [144].”
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21 · cited 1×
“In various cancers, including CRC, miRNAs that target ABC transporters have been reported to modulate the chemosensitivity of cancer cells [102,103].”
Kim, J., Choi, K.-W., Lee, J., Lee, J., Lee, S., Sun, R., & Kim, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58612 · Cited by 21 · cited 1×
“In CRC cells, Wnt pathway inhibition has been demonstrated to inhibit cell proliferation, reduce tumor-initiating cell numbers, and impair tumor growth in CRC xenograft models [190–193].”
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15215243 · Cited by 21 · cited 3×
“This type of targeted therapy is only effective in the absence of mutations in , HER2-positive) ) for CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34].”
Ying, L., Yan, F., Williams, B. R., Xu, P., Li, X., Zhao, Y., Hu, Y., Wang, Y., Xu, D., & Dai, J. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12854 · Cited by 20 · cited 1×
“For instance, targeting enzymes like Enhancer of Zeste Homologue 2 (EZH2; subunit of HMT that trimethylates H3K27) has shown promising inhibitory effects on proliferation, migration, invasion, and colony/sphere formation of CRC cell lines [169,170].”
Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
Brisset, M., Mehlen, P., Meurette, O., & Hollande, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231416 · Cited by 20 · cited 2×
“The Notch signaling pathway plays a significant role in CSC self-renewal and cell fate decisions, and dysregulated Notch signaling contributes to CRC progression, chemore-sistance, and CSC heterogeneity [196].”
The Role of ATP-Binding Cassette Subfamily A in Colorectal Cancer Progression and Resistance
Alketbi, L., Al-Ali, A., Talaat, I. M., Hamid, Q., & Bajbouj, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021344 · Cited by 20 · cited 2×
“ABC transporters actively pump a wide range of anticancer drugs out of cancer cells, thereby reducing their intracellular concentrations [44].”
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18 · cited 1×
“For instance, in CRC, fibroblast activation protein was identified as a strong candidate for antibody conjugate therapy since it was found to be highly expressed in most CRC tissues and absent in >90% of adjacent normal tissues (colon and liver) [225].”
Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228 Impairs Tumor Growth of Colon Cancer
KIM, J. Y., PARK, G., KRISHNAN, M., HA, E., & CHUN, K.-S. (2019) · Anticancer Research · doi:10.21873/anticanres.13514 · Cited by 18
Wang, J., Zhang, X., Zhang, J., Chen, S., Zhu, J., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02353-5 · Cited by 18 · cited 1×
“In addition, different ncRNAs have been shown to contribute to resistance against 5-FU, oxaliplatin, and anti-EGFR therapies by various mechanisms [62–64].”
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116220 · Cited by 18 · cited 5×
“A second key approach for targeting colorectal CSCs involves the suppression of specific signaling pathways that are critical for CSC maintenance and proliferation [69,71,72].”
InfluentialColorectal Cancer Stem Cells and Targeted Agents
Zhao, H., Han, R., Wang, Z., Xian, J., & Bai, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122763 · Cited by 18
Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., et al. (2024) · Cancers · doi:10.3390/cancers16203441 · Cited by 14 · cited 1×
“For instance, PARP inhibition was shown to sensitize CRC cells to irinotecan, which was dependent upon homologous recombination deficiency [135].”
Si, Y., Li, L., Zhang, W., Liu, Q., & Liu, B. (2022) · Oncology Reports · doi:10.3892/or.2022.8397 · Cited by 13
Lysyl oxidase inhibitors in colorectal cancer progression
Liu, M., Wang, J., & Liu, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2024.102233 · Cited by 13 · cited 2×
“Various drugs targeting LOXL2 are currently under investigation for CRC treatment, including β -aminopropionitrile, simtuzumab, and PXS compounds [220].”
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024) · Cancers · doi:10.3390/cancers16183136 · Cited by 12 · cited 1×
“A WEE1 inhibitor was recently reported to exert anticancer effects in CRC cells, particularly in those with TP53 mutations [140].”
Azarifar, Z., Amini, R., Tanzadehpanah, H., Afshar, S., & Najafi, R. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08888-2 · Cited by 11 · cited 1×
“For example, treatment of colon cancer cell lines with the compound all-trans retinoic acid inhibited cell proliferation, decreased CSCs, induced differentiation, and enhanced the efficacy of 5-FU in vitro [205,206].”
Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11 · cited 2×
“However, since anti-angiogenic therapies lead to only modest increases in survival for CRC patients, there is a need for biomarkers for patient stratification, integration of novel combinations of anti-angiogenic drugs with immunotherapy, and better preclinical models of metastatic CRC [211].”
An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer
Shahzad, M., Hameed, H., Amjad, A., Khan, M. A., Qureshi, I. S., Hameed, A., Saeed, A., & Munir, R. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03482-0 · Cited by 7
Colorectal Cancer Stem Cells and Targeted Agents
(2023) · doi:10.20944/preprints202310.0988.v1 · Cited by 7
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6 · cited 1×
“In addition, dual immunotherapies are being investigated, including two ICI combinations in patients with MSI-H/dMMR metastatic CRC to overcome primary resistance to ICI monotherapy [241].”
Targeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6 · cited 7×
“A second key approach for targeting colorectal CSCs involves the suppression of specific signaling pathways that are critical for CSC maintenance and proliferation [69,71,72].”
InfluentialBioinformatic Identification of TP53 Gene Mutation Hotspots in Colorectal Cancer
Kovács, Z., Sugimura, H., György, T. A., Osvath, E., Manirakiza, F., & Gurzu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126612 · Cited by 5 · cited 1×
“Loss-of-function mutations in the tumor suppressor genes TP53 (mutated in 50–60% of CRCs) and SMAD4 (mutated in ~15% of CRCs) also occur frequently [13,16].”
Cited by
Kantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 28
“…found in CMS1, the BEACON regimen—which consists of cetuximab, binimetinib, and encorafenib—has also demonstrated efficacy in treating BRAF-mutant mCRC. Adjuvant chemotherapy is not clearly linked to improved overall survival in CMS1 malignancies as compared to standard chemotherapy ([53]– [54]).”
Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance
Han, J., Liang, W., & Li, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1753180 · Cited by 21
“Drug resistance can be intrinsic, present at diagnosis, or acquired during treatment, often leading to tumor recurrence and metastasis (Haynes and Manogaran, 2025; Oktavianda and Giselvania, 2024).”
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications
Peshin, S., Bashir, F., Kodali, N. A., Dharia, A. A., Zaiter, S., Singal, S., & Moka, N. (2025) · Antibodies · doi:10.3390/antib14030058 · Cited by 18
“Alternatively, VEGF inhibitors like bevacizumab or novel LAG-3 inhibitors may help overcome resistance by modulating the tumor microenvironment [57,58].”
Shahsavani, M. B., Heidari, M., Yousefi, R., & Moosavi‐Movahedi, A. A. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70208 · Cited by 15
“…share chal- lenges—dose-limiting toxicities, nonspecific cytotoxicity, and multifactorial drug resistance arising from enhanced DNA repair, decreased uptake, or increased efflux (Galluzzi et al. 2012; Dilruba and Kalayda 2016; Haynes and Manogaran 2025; Richardson et al. 2023; Matsuo et al. 2010).”
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
“Drug resistance is a critical, multimechanistic challenge in cancer treatment, involving both endogenous and exogenous factors [314].”
Metadata
- Authors
- Haynes, J., & Manogaran, P.
- Affiliations
- Marshall University (US)
- Corresponding author
- Haynes, Jennifer
- ORCID
- Manogaran, Prasath
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-02-25
- Volume
- 26
- Issue
- 5
- Pages
- 1988
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11901061
- OpenAlex
- W4407920293
- Cited by
- 82
- References
- 249
- Citations by year
- 2026: 57 · 2025: 24
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, drug resistance, resistance mechanisms, epigenetic modifications, tumor heterogeneity, tumor microenvironment, drug transporters, DNA damage response, cell death pathways, cancer stem cells, signaling pathways, therapeutic target
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epigenesis, Genetic, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.